Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
Date:3/18/2013

ndo on BDSI's balance sheet as of December 31, 2012.  As previously reported, this deferral of revenue had no impact (and will have no impact) on BDSI's cash position or its ability to use these funds in connection with its business plans.  Further details regarding this restatement can be found in such amended Form 10-Q reports and BDSI's 2012 Form 10-K, all of which were filed with the SEC on March 18, 2013.

2012 Corporate Update

By way of review, the following are key events that occurred at BDSI over the past 15 months:

  • BEMA Buprenorphine - Chronic Pain.  Early in 2012, BDSI signed a worldwide license and development agreement with Endo for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain.  The agreement, worth up to $180 million to BDSI if all milestones and thresholds are met, resulted in the payment of a $30 million license fee at signing and $15 million in April 2012 upon the granting of a patent extending the exclusivity of BEMA products containing buprenorphine from 2020 to 2027.  The partnership also grants BDSI the potential to receive sales threshold payments as well as a tiered mid- to upper-teen royalty on net sales in the U.S. following FDA approval.  

    In August, BDSI and Endo initiated the Phase 3 clinical studies of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.  Two efficacy studies, one in opioid naïve and one in opioid experienced subjects, are currently enrolling patients. 
  • BUNAVAIL - Opioid Dependence.  BUNAVAIL, formerly referred to as BEMA Buprenorphine/Naloxone or BNX, is being developed for the treatment of opioid dependence and utilizes the patented BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine combined with the opioid antagonist nalo
    '/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Announces $40 Million Registered Financing
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... Nov. 21, 2014 MEDITE Group acquired by CytoCore, ... and the 3 rd quarter sales ended September 30, ... $448,000 for the nine months ended September 2014 and a ... our 3 rd quarter is usually a seasonable weak ... July into September for many countries worldwide, we are proud ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... , NEW YORK, ... research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The fast developing ... of activity with pharmaceutical companies adding chiral expertise to ...
... , NEW YORK, ... research report is available in its catalogue: , ... of Market Trends & Opportunities , http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html ... years of meager clinical outcomes owing to lack of ...
Cached Medicine Technology:Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Sandbridge ... equity investments in the consumer brand sector, acquired ... investment will be used to help fund BackJoy’s ... pipeline rollout, particularly its proprietary apparel and footwear ... join BackJoy’s Board of Directors. , BackJoy is ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- A clinical trial of ... been halted a year early because the results show ... the disease and reduce the risk of stroke. ... 25 medical centers in the United States and Canada, ... Lung, and Blood Institute (NHLBI). Researchers compared monthly ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... Jan. 27 Bio-Reaction Industries, LLC (BRI),received the ... Special,Services by the Environmental Business Journal for 2008. ... Bio-Reactions progression as a worldwide leader of,bio-oxidation technology. ... amazing growth in 2008, increasing,revenue by 300% for ...
... 9% Over 2007 to $765.3 Million; Positive Operating Cash ... 27 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... year ended December 31, 2008. The Company reported total ... 31, 2008, which includes net product sales of $184.9 ...
... imperative of addressing chronic disease crisisWASHINGTON, Jan. 27 ... today urged President Obama and Congress to make ... components of reform efforts. Topping its list of ... leaders to realign incentives in the health care ...
... researchers say , , TUESDAY, Jan. 27 (HealthDay News) -- ... potential new method of promoting recovery from chronic stress ... "fight or flight" response. , The approach focuses on ... body,s major control systems. The HPA axis uses hormone ...
... Chest radiation indicates need for earlier screening, study notes, ... of female childhood cancer survivors under the age of ... treatment are not following the recommended advice to get ... , The recommendation suggests starting screening mammograms at age ...
... Calif., Jan. 27 Omnicell, Inc.,(Nasdaq: OMCL ) ... been awarded a five year contract by Duke University ... , Duke University Health ... Hospital, Duke Raleigh Hospital, and many other clinical,facilities. , ...
Cached Medicine News:Health News:Bio-Reaction Industries Recognized as Leader in Technology 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:National Partnership Releases Principles for Meaningful Health Reform 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:Omnicell is Awarded Contract by Major National Academic Medical Center 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: